Copyright
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Stem Cells. Dec 26, 2020; 12(12): 1652-1666
Published online Dec 26, 2020. doi: 10.4252/wjsc.v12.i12.1652
Published online Dec 26, 2020. doi: 10.4252/wjsc.v12.i12.1652
Umbilical cord-derived mesenchymal stem cells preconditioned with isorhamnetin: potential therapy for burn wounds
Shazmeen Aslam, Irfan Khan, Fatima Jameel, Midhat Batool Zaidi, Asmat Salim, Stem Cell Laboratory, Dr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Karachi 74700, Sindh, Pakistan
Author contributions: Aslam S performed all experiments, analyzed the data and wrote the first draft of the manuscript; Khan I and Salim A conceived the idea, designed the experiments, and assisted in data analysis; Salim A wrote the final manuscript; Jameel F assisted in the in vivo models and wrote part of the manuscript; Zaidi MB assisted in the in vitro studies and image analysis; all authors approved the final version of the article.
Institutional review board statement: The study was reviewed and approved by the Independent Ethics Committee of International Center for Chemical and Biological Sciences, University of Karachi (ICCBS/IEC-036-HT-2018/Protocol/1.0).
Institutional animal care and use committee statement: The study was reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of the International Center for Chemical and Biological Sciences, University of Karachi (Animal study protocol number: 2018-0018).
Conflict-of-interest statement: The authors have nothing to disclose.
Data sharing statement: Informed consent regarding the experiments in the current study was received from all participants. No additional data are available.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared according to the ARRIVE guidelines.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Asmat Salim, PhD, Professor, Stem Cell Laboratory, Dr. Panjwani Center for Molecular Medicine and Drug Research, ICCBS, University of Karachi, University Road, Karachi 74700, Sindh, Pakistan. asmat.salim@iccs.edu
Received: July 30, 2020
Peer-review started: July 30, 2020
First decision: September 17, 2020
Revised: October 1, 2020
Accepted: October 26, 2020
Article in press: October 26, 2020
Published online: December 26, 2020
Processing time: 149 Days and 18.5 Hours
Peer-review started: July 30, 2020
First decision: September 17, 2020
Revised: October 1, 2020
Accepted: October 26, 2020
Article in press: October 26, 2020
Published online: December 26, 2020
Processing time: 149 Days and 18.5 Hours
Core Tip
Core Tip: In this study, we propose an improved cell-based therapeutic approach using a cytoprotective chemical compound, isorhamnetin to precondition human umbilical cord mesenchymal stem cells (MSCs) for second degree burn wounds. The findings of this study suggest that transplantation of preconditioned MSCs in the rat burn wound model decreases wound progression by the downregulation of inflammatory cytokines and restoration of tissue architecture. The study outcome may lead to an effective cell-based treatment strategy for burn wounds to accelerate wound healing and promote skin regeneration.